Certain types of life science research involving “high consequence pathogens and toxins” would be subject to new review and risk mitigation procedures which might include classification of the research or termination of the funding, according to a U.S. government policy issued yesterday by the National Institutes of Health.
The policy applies to research involving 15 specified biological agents and toxins which “pose the greatest risks of deliberate misuse with most significant potential for mass casualties or devastating effects to the economy, critical infrastructure or public confidence.”
Research that increases the lethality or transmissibility of the agent or toxin, or otherwise enhances its harmful consequences, will be subject to the new review procedures.
Based on the outcome of the review, a risk mitigation plan may be developed. If less restrictive measures were deemed inadequate, the new policy would allow for national security classification of the research or termination of government funding.
See “United States Government Policy for Oversight of Life Sciences Dual Use Research of Concern,” March 29, 2012.
See also “U.S. Requires New Dual-Use Biological Research Reviews” by David Malakoff, Science Insider, March 29.
Given the unreliability of private market funding for agricultural biotechnology R&D, substantial federal funding through research programs such as AgARDA is vital for accelerating R&D.
“Given the number of existential crises we must collectively confront, I have found policy entrepreneurship to be a fruitful avenue towards doing some of that work.”
We sit on the verge of another Presidential election – an opportunity for meaningful, science-based policy innovations that can appeal to lawmakers on both sides of the aisle.
Outdated Bureau of Labor Statistics classifications hampers the federal government’s ability to design and implement effective policies for emerging technologies sectors.